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Abstract
Uridine adenosine tetraphosphate (Up4A), a novel endothelium-derived vasoactive agent, is 
proposed to play a role in cardiovascular disorders and induces aortic contraction through 
activation of cyclooxygenases (COX). We and others demonstrated that activation of A1 or A3 
adenosine receptors (AR) results in vascular contraction via thromboxane (TX) A2 production. 
However, the mechanisms of Up4A-induced vascular contraction in mouse aorta are not 
understood. We hypothesize that Up4A-induced aortic contraction is through COX-derived TXA2 
production, which requires activation of A1 and/or A3AR. Concentration responses to Up4A were 
conducted in isolated aorta. The TXB2 production, a metabolite of TXA2, was also measured. 
Up4A (10−9–10−5 M) produced a concentration-dependent contraction >70%, which was markedly 
attenuated by COX and COX1 but not by COX2 inhibition. Notably, Up4A-induced aortic 
contraction was blunted by both TX synthase inhibitor ozagrel and TXA2 receptor (TP) antagonist 
SQ29548. Surprisingly, A3AR deletion had no effect on Up4A-induced contraction. Moreover, 
A1AR deletion or antagonism as well as A1/A3AR deletion potentiated Up4A-induced aortic 
contraction, suggesting a vasodilator influence of A1AR. In contrast, non-selective purinergic P2 
receptor antagonist PPADS significantly blunted Up4A-induced aortic contraction to a similar 
extent as selective P2X1R antagonist MRS2159, the latter of which was further reduced by 
addition of ozagrel. Endothelial denudation almost fully attenuated Up4A-induced contraction. 
Furthermore, Up4A (3 µM) increased TXB2 formation, which was inhibited by either MRS2159 or 
ozagrel. In conclusion, Up4A-induced aortic contraction depends on activation of TX synthase and 
TP, which partially requires the activation of P2X1R but not A1 or A3 AR through an 
endothelium-dependent mechanism.
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1. Introduction
The endothelium releases a variety of vasodilators, such as nitric oxide (NO) and 
prostacyclin, and vasoconstrictors, such as endothelin and thromboxane (TX) A2 (1, 2). A 
novel endothelium-derived vasoactive factor uridine adenosine tetraphosphate (Up4A) has 
been initially identified as a vasoconstrictor in isolated kidney of rats (3). Up4A is the first 
dinucleotide found in living organisms that contains both purine and pyrimidine moieties 
and therefore can exert its vasoconstrictor effects through both the purinergic P1 (also 
known as ARs) and P2 receptors (P2R) (3, 4). Indeed, several in vitro studies have indicated 
that Up4A induces vascular contraction through purinergic receptors. Thus, vasoconstriction 
was observed in rat renal artery through P2X1R (3), in rat aorta through P1 and P2XR (5), 
and in rat pulmonary arteries through P2YR (6). Furthermore, vasoconstriction was also 
observed in mouse renal arterioles (7), mouse aorta (8) and rat mesenteric arteries (9), 
although Up4A has been subsequently found to be able to exert a vasodilator effect in rat 
aorta (5), isolated perfused rat kidney (10) and porcine coronary arteries (11, 12) as well as 
to induce hypotension in conscious rats (8). The observations that plasma concentrations of 
Up4A detected in juvenile hypertensive subjects are elevated (13), as well as intra-aortic 
injection of Up4A increases mean arterial blood pressure in intact animal (3), suggest a role 
for Up4A in the pathogenesis of hypertension. At post-receptor levels, Up4A-induced 
vascular contraction was markedly attenuated by cyclooxygenase (COX) inhibition in 
mouse aorta (8), implying a modulatory role of vasoconstrictor prostanoids in Up4A-
mediated vascular tone.
TXA2, one of the vasoconstrictor prostanoids, is produced from arachidonic acid by COX 
pathway (1, 14). Subsequently, COX converts arachidonic acid into intermediate 
endoperoxide, the latter of which is catalyzed by TX synthase eventually leading to the 
production of TXA2 (1). By activating TXA2 receptors (TP), TXA2 has been reported to 
exert a vasoconstrictor effect in various vascular beds, thereby potentially contributing to the 
development of cardiovascular diseases such as hypertension (1). Previous studies have 
shown that TXA2 is produced and TP is activated by activation of P2XR and P2YR, which 
subsequently leads to vasoconstriction in canine basilar arteries (15), human umbilical and 
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chorionic vessels (16) as well as rat aorta (17). In addition to P2R, involvement of A1AR has 
been observed in TXA2-mediated vasoconstriction in feline pulmonary circulation (18). 
Recently, we demonstrated that activation of A3AR results in TXA2 production, which leads 
to vascular contraction in mouse aorta (19). All these observations indicate that TXA2 can 
be generated via activation of purinergic receptors resulting in vascular contraction. More 
importantly, the observations that Up4A activates TP resulting in renal vasoconstriction and 
Up4A increases TXA2 production in renal arteries of rats (20), suggest a link between 
Up4Amediated vascular contraction and the involvement of TXA2. Although Up4A-induced 
vasoconstriction in mouse aorta was attenuated by COX inhibition (8), the underlying 
mechanisms remain obscure.
Consequently, with particular focus on mouse aorta, we hypothesized that Up4A-induced 
vascular contraction in mouse aorta is through COX-derived TXA2 production, which 
requires activation of A1AR and/or A3AR. Specifically, we aimed to firstly investigate 
whether TXA2 is produced and/or TP is activated in response to Up4A that contributes to 
vascular contraction in mouse aorta, and secondly, to determine the A1AR and/or A3AR 
involvement in Up4A-induced aortic contraction. Our findings from this study indicate that 
neither A1AR nor A3AR contributes to Up4A-induced aortic contraction. Since activation of 
P2R, particularly P2X1R, has been shown to be a vasoconstrictor purinergic receptor 
contributing to Up4A-mediated vasoconstriction (3, 21), the third aim of our study was to 
further explore the involvement of P2R, particularly P2X1R, in Up4A-induced vascular 
contraction in mouse aorta.
2. Materials and Methods
2.1 Drugs and solutions
Acetylcholine, 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX), indomethacin, MRS2159, N-
[2-(Cyclohexyloxy)-4-nitrophenyl]-methanesulfonamide (NS398), (E)-3-[4-(Imidazol-1-
ylmethyl)phenyl]propenoic acid hydrochloride hydrate (ozagrel), phenylephrine, 
pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid (PPADS) and 5-(4-Chlorophenyl)-1-
(4-methoxyphenyl)-3-trifluoromethyl pyrazole (SC560) were all purchased from Sigma-
Aldrich (St. Louis, MO, USA). Up4A was obtained from Biolog Life Science (Bremen, 
Germany). [1S-[1α,2α(Z),3α,4α]]-7-[3-[[2-[(phenylamino)carbonyl]hydrazino]methyl]-7-
xabicyclo[2.2.1] hept-2-yl]-5-heptenoic acid (SQ29548) and thromboxane B2 enzyme 
immunoassay (EIK) kit were purchased from Cayman Chemical (Ann Arbor, MI, USA). 
Indomethacin, DPCPX, NS398, SC560 and SQ29548 were firstly dissolved in DMSO. All 
subsequent dilutions (at least 1000 fold) and other drugs were obtained with distilled water. 
PPADS and MRS2159 were protected from light.
2.2 Animals
All experimental protocols were approved by the Institutional Animal Care and Use 
Committee at School of Medicine, West Virginia University. Wild type (WT) mice 
(C57BL/6 background) were purchased from The Jackson Laboratory (Bar Harbor, ME). 
A1AR knockout (KO), A3AR KO and A1/A3AR double KO (DKO) mice were obtained 
from Dr. Stephen Tilley (University of North Carolina, Chapel Hill, NC). A1AR and A3AR 
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KO mice, both backcrossed 12 generations to the WT, were bred to generate A1/A3AR 
double heterozygotes. Double heterozygotes were intercrossed, and 1/16th of the offspring 
were A1/A3AR DKO. A1/A3AR DKO breeding pairs were then established. Mice were 
caged in a 12:12-h light-dark cycles with free access to standard chow and water. Mice with 
age from 14 to 16 wk of either sex were used in this study.
2.3 Tissue preparation and isometric force measurement
Mice were euthanized by anesthesia with pentobarbital sodium (65 mg/kg i.p.) followed by 
thoracotomy and removal of aorta. The aorta was cleaned by removing fat and connective 
tissues that was then cut transversely into 3 to 4 mm rings as described previously (19, 22). 
In a subset of rings, the endothelium was removed mechanically with a piece of thin wire by 
gently rolling it back and forward. Subsequently, the aortic rings were mounted vertically 
between two wire hooks and then suspended in 10 ml organ baths containing Krebs-
Henseleit buffer. The Krebs-Henseleit buffer (pH 7.4) containing (in mM) 118 NaCl, 4.8 
KCl, 1.2 MgSO4, 1.2 KH2PO2, 25 NaHCO3, 11 glucose and 2.5 CaCl2 was maintained at 
37°C aerated with 95% O2/5% CO2. For measurement of isometric force response (with 
fixed range precision force transducer, TSD, 125 C; Biopac system), aortic rings were 
equilibrated for 60 min with a resting force of 1 g (22, 23) and change of the Krebs solution 
at a 15 min interval. At the end of equilibration period, tissues were exposed to 50 mM KCl 
twice to check the contractility of individual aortic rings. Endothelial integrity was verified 
by observing dilation to 1 µM acetylcholine after preconstriction with 1 µM phenylephrine 
(22). The non-denuded rings that respond appropriately (relaxation >50%) and denuded 
rings that did not respond to acetylcholine were used in this study. Thereafter, rings were 
allowed to equilibrate in fresh organ bath fluid for 30 min before initiating different 
experimental protocols. Since previous study (8) as well as our current observation showed a 
very mild and transient contraction by Up4A in aortic rings at basal condition (data not 
shown), all the experiments were performed upon a steady contraction by 1 µM 
phenylephrine. The aortic rings that did not elicit reproducible and stable contraction with 
phenylephrine were excluded from the study. In experiments where the effect of an 
antagonist was measured, it was added 30 min before preconstriction with phenylephrine 
and was present throughout the experiments. Only one protocol was executed per ring and 
within one protocol all rings were obtained from different animals.
2.4 Organ bath experimental protocols
Preconstricted aortic rings were subjected to Up4A concentration responses (10−9–10−5 M). 
In accordance with previous studies (8), Up4A, at a dose of 10−5 M, produced 
vasoconstriction followed by vasodilation in mouse aorta, indicating a biphasic effect of 
Up4A. Since the aim of the present study was to elucidate the mechanisms of Up4A-induced 
contraction in mouse aorta, the observation that Up4A-induced vasodilation at a dose of 10−5 
M was excluded.
Up4A-induced aortic contraction was observed to be attenuated by COX inhibition (8), to 
investigate which COX subtype was involved in this process, rings were subjected to Up4A 
(10−9–10−5 M) in the absence and presence of non-selective COX inhibitor indomethacin 
(10 µM) (19), selective COX1 inhibitor SC560 (10 nM) (19) and selective COX2 inhibitor 
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NS398 (1 µM) (19). To test whether the involvement of vasoconstrictor prostanoids was 
through TXA2 production or TP activation, Up4A concentration responses were performed 
in aortic rings in the absence and presence of TX synthase inhibitor ozagrel (10 µM) (24) 
and TP antagonist SQ29548 (1 µM) (19), respectively.
Since both A1AR and A3AR have been shown to be involved in TXA2-mediated vascular 
contraction (18, 19), aortic rings from WT, A1AR KO, A3AR KO and A1/A3AR DKO mice 
were exposed to Up4A concentration responses (10−9–10−5 M). In addition, aortic rings of 
WT were subjected to Up4A in the absence and presence of selective A1AR antagonist 
DPCPX (10 nM) (25). To investigate the involvement of P2R in Up4A-induced vascular 
contraction, aortic rings of WT were exposed to Up4A in the absence and presence of non-
selective P2R antagonist PPADS (10 µM) (12) and selective P2X1R antagonist MRS2159 
(30 µM) (26), respectively.
To assess whether TXA2 production requires activation of P2X1R, aortic rings were treated 
with Up4A in the absence and presence of MRS2159, ozagrel and the combination of 
MRS2159 and ozagrel.
To investigate the possible endothelial involvement of Up4A-induced aortic contraction, 
Up4A concentration responses were conducted in endothelium –non-denuded and –denuded 
rings. To identify the compartment in which P2X1R locates to generate TXA2 in response to 
Up4A, denuded aortic rings were exposed to Up4A in the absence and presence of MRS2179 
and ozagrel, respectively. The various antagonists used in the present study do not interfere 
with 1 µM phenylephrine response within each figure panels and there is no significant 
difference in 1 µM phenylephrine response between WT and KO mice (data not shown).
2.5 Measurement of TXA2 release
TXB2, a metabolite of TXA2, was measured according to protocols from previous studies 
(20, 27), with slight modification. Briefly, cleaned mouse aortic rings were incubated at 
37°C for 60 min in a siliconized tube containing 1 ml of Krebs-Henseleit buffer, as 
described for organ bath studies. After incubation, rings were treated with MRS2159 (30 
µM) or ozagrel (10 µM), and incubated for another 30 min in 500 µl Krebs buffer. 
Thereafter, Up4A (3 µM) or vehicle (water) was added for 10 min. Then the aortic rings 
were removed and the tubes were freeze-clamped in liquid nitrogen and stored at −80°C for 
subsequent analysis. TXB2 was measured using an EIA kit (Cayman Chemicals, Ann Arbor, 
MI, USA). The undiluted 50 µl samples were used. The various assays were performed as 
described in the manufacturer’s booklet. The amount of TXB2 is expressed in picograms per 
milligram wet weight of the aortic rings.
2.6 Data analysis and statistics
Vascular contraction responses to Up4A were expressed as percentage of contraction to 
phenylephrine. The effects of drug treatment on the Up4A concentration responses were 
assessed using two-way ANOVA for repeated measures. The effects of drug treatment on 
Up4A-induced TXA2 production were analyzed using one-way ANOVA. Statistical 
significance was accepted when P < 0.05 (two-tailed). Data are presented as means ± SEM.
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3.1 Involvement of COX1 in Up4A-induced aortic contraction
In preconstricted aortic rings, Up4A produced a concentration-dependent contraction over 
70% (Fig. 1). In accordance with previous studies (8), Up4A-induced aortic contraction was 
markedly attenuated by non-selective COX inhibitor indomethacin (Fig. 1A). Furthermore, 
Up4A-induced aortic contraction was significantly attenuated by selective COX1 inhibitor 
SC560 (Fig. 1B), but not by selective COX2 inhibitor NS398 (Fig. 1C). These observations 
indicate that Up4A-induced contraction in mouse aorta is attributed to vasoconstrictor 
prostanoids produced by COX1 activation.
3.2 Involvement of TXA2 in Up4A-induced aortic contraction
To investigate whether the involvement of vasoconstrictor prostanoids in Up4A-induced 
aortic contraction is TXA2, we performed Up4A concentration responses in isolated aortic 
rings in the absence and presence of either TX synthase inhibition or TP antagonism. Up4A-
induced aortic contraction was dramatically attenuated by TX synthase inhibitor ozagrel 
(Fig. 2A) and TP antagonist SQ29548 (Fig. 2B), respectively. These findings indicate that 
the involvement of vasoconstrictor prostanoids in Up4A-induced aortic contraction appears 
to be through TX synthase and TP activation.
3.3 Involvement of purinergic P1 receptors in Up4A-induced aortic contraction
Since both A1AR and A3AR have been shown to be involved in TXA2-mediated vascular 
contraction (18, 19), we next studied the involvements of A1AR and A3AR in Up4A-
induced aortic contraction. Up4A induced a concentration-dependent aortic contraction in 
WT mice, which was comparable to that in A3AR KO mice (Fig. 3A). Surprisingly, Up4A-
induced aortic contraction was potentiated in A1AR KO as compared to WT mice (Fig. 3B). 
A similar observation was also found in A1/A3AR DKO mice in which Up4A-induced aortic 
contraction was enhanced as compared to WT mice (Fig. 3C). These findings suggest that 
A3ARs does not appear to be involved in Up4A-induced contraction in mouse aorta. 
However, A1AR may exert a vasodilator rather than vasoconstrictor influence in Up4A-
induced aortic contraction.
The observation that Up4A-induced aortic contraction was enhanced in A1AR KO or A1/
A3AR DKO mice may be due to a compensatory mechanism that often occurs using 
genetically modified mice (28). To further confirm the role of A1AR in Up4A-induced aortic 
contraction, we performed concentration responses to Up4A in isolated aortic rings from WT 
mice in the absence and presence of pharmacological inhibition by the selective A1AR 
antagonist. Similar to the observations from A1AR KO or A1/A3AR DKO, selective A1AR 
antagonist DPCPX significantly potentiated Up4A-induced contraction in mouse aorta (Fig. 
3D). This finding supports the observation that A1AR may exert a vasodilator influence, 
which suppresses Up4A-induced vascular contraction in mouse aorta.
3.4 Involvement of purinergic P2 receptors in Up4A-induced aortic contraction
Based on the findings that neither A1AR nor A3AR exerts a vasoconstrictor influence 
contributing to Up4A-induced aortic contraction, we next investigated the involvement of 
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P2R in this process. Non-selective P2R antagonist PPADS (Fig. 4A) and selective P2X1R 
antagonist MRS2159 (Fig. 4B) significantly attenuated Up4A-induced vascular contraction 
in mouse aorta, respectively. To further study whether Up4A-induced aortic contraction via 
TXA2 production requires activation of P2X1R, isolated aortic rings were exposed to 
MRS2159, ozagrel or the combination of both MRS2159 and ozagrel. Up4A-induced aortic 
contraction was significantly reduced by MRS2159, which was slightly but significantly 
further attenuated by addition of ozagrel (Fig. 5). However, the inhibition of Up4A-induced 
aortic contraction by a combination of MRS2159 and ozagrel was similar in magnitude to 
that obtained by ozagrel alone (Fig. 5). All together, these observations indicate that Up4A-
induced vascular contraction in mouse aorta is through TXA2 production, which partially 
requires the activation of P2X1R.
3.5 Endothelium-dependency of aortic contraction produced by Up4A
To elucidate the role of endothelium in Up4A-induced aortic contraction, endothelium-
denuded aortic rings were subjected to Up4A concentration responses in the absence and 
presence of P2X1R antagonist MRS2159 and TX synthase inhibitor ozagrel. Up4A-induced 
aortic contraction was almost completely blunted by endothelium denudation either with or 
without MRS2159 or ozagrel (Fig. 6), indicating that Up4A-induced contraction in mouse 
aorta is mainly endothelium-dependent.
3.6 TXA2 production generated by Up4A in isolated aortic rings
To further test our finding that TXA2 is involved in Up4A-induced aortic contraction, TXB2, 
a metabolite of TXA2, was measured in isolated intact aortic rings upon Up4A stimulation. 
The level of TXB2 was greatly increased in Up4A (3 µM)-treated tissues as compared to 
vehicle (Fig. 7). Furthermore, Up4A-increased TXB2 level was dramatically inhibited by 
either P2X1R antagonist MRS2159 or TX synthase inhibitor ozagrel (Fig. 7). These findings 
suggest that Up4A is capable of generating TXA2, which partially requires activation of 
P2X1R in mouse aorta.
4. Discussion
The main findings of the present study are: 1) Up4A produced a concentration-dependent 
vascular contraction (>70%), which was attenuated by non-selective COX and selective 
COX1 but not COX2 inhibition; 2) Up4A-induced aortic contraction was markedly blocked 
by TX synthase inhibition and TP antagonism, respectively; 3) A3AR deletion had no effect 
on Up4A-induced aortic contraction, whereas A1AR deletion or antagonism as well as A1/
A3AR deletion potentiated Up4A-induced contraction; 4) In contrast, non-selective P2R 
antagonist PPADS attenuated Up4A-induced contraction, while selective P2X1R antagonist 
MRS2159 similarly attenuated Up4A-induced aortic contraction, which was further reduced 
by TX synthase inhibitor ozagrel; 5) Furthermore, endothelial denudation almost fully 
blunted Up4A-induced aortic contraction either with or without MRS2159 or ozagrel; 6) and 
finally, TXA2 production was significantly increased by Up4A in intact isolated aortic rings, 
which was inhibited by either MRS2159 or ozagrel. The implications of these findings are 
discussed below.
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Up4A was first identified as a potent endothelium-derived vasoconstrictor in rat perfused 
kidney (3). Several subsequent studies have confirmed that Up4A produces vasoconstriction 
in rat renal artery (3), aorta (5), gastric smooth muscle (29) and pulmonary arteries (6). 
Furthermore, vasoconstriction was observed in mouse renal arterioles (7) and aorta (8). 
Although, there is evidence that Up4A can produce vasodilation in isolated aortic rings of 
rats (5), porcine coronary small arteries (11, 12), human and mouse colon (30) as well as 
induce hypotension in conscious rats (8). All together, these studies suggest that the vascular 
responses to Up4A likely depend on the type of vascular beds and species studied (4).
In mouse aorta, Hansen and colleagues (8) demonstrated that in preconstricted aortic rings, 
cumulative addition (10−7–10−5 M) of Up4A produced vasoconstriction followed by 
relaxation at a dose of 10−5 M, indicating a biphasic effect of Up4A. Consistent with the 
vasodilator effect induced by Up4A at a dose of 10−5 M, we observed a similar relaxation of 
41 ± 0.06% in the present study as compared to the report by Hansen et. al. (46 ± 6% 
relaxation) (8). However, cumulative addition of Up4A (10−9–10−5 M) produced a 
concentration-dependent contraction over 70%, which was inconsistent with the previous 
study in which cumulative addition of Up4A (10−7–10−5 M) caused aortic contraction of 18 
± 2%, 76 ± 16% and 18 ± 6%, respectively (8). This disparity may not be attributed to the 
different strain of animals (the same C57BL/6 mice with similar age range), but might due 
to the different number of animals (n) used in the studies in which variable vascular 
responses to Up4A between each individual animals may occur, as a large number of control 
animals were pooled in the present study (n=49) as opposed to the study by Hansen et. al. 
with an ‘n’ of only six (8). For the sake of comparing vasoconstrictor effect of Up4A 
(>70%), another vasoconstrictor agonist U46619 (TXA2 analogue 9,11-Dideoxy-11α, 9α -
epoxymethanoprostaglandin F2α) concentration responses (10−9 M–10−6 M) were 
performed in the same preparation that produced a dose-dependent contraction up to ~240%, 
which almost reaches the maximal contraction. Together with the vasoconstrictor effects of 
ATP (~50%) (31) and activation of ARs (~30%) in isolated aorta, this may indicate that 
Up4A is a relatively potent vasoconstrictor, which submaximally contracts mouse aorta. 
Notably, infusion of Up4A (10−9–10−5 M) into isolated mouse hearts results in a dose-
dependent reduction in coronary flow by ~40% (unpublished) as well as intra-aortic 
injection of Up4A (100 nmol) increases mean arterial blood pressure by ~25% in 
anesthetized rats (3), suggesting a potential vasoconstrictor influence of Up4A in vivo.
In accordance with previous finding by Hansen et. al. (8), Up4A-induced aortic contraction 
was markedly attenuated by non-selective COX inhibition with indomethacin, suggesting an 
involvement of vasoconstrictor prostanoids. Subsequent observations that Up4A-induced 
aortic contraction was blunted by selective-COX1 but not selective COX2 inhibition further 
supports the concept that activation of COX1 but not COX2 primarily contributes to 
generation of vasoconstrictor prostanoids in mouse aorta (32, 33). On the other hand, the 
lack of involvement of COX2 in Up4A-mediated aortic contraction could be due to the fact 
that COX2, an inducible enzyme, predominantly plays a role under inflammatory /diseased 
conditions (34). Indeed, one of the recent studies in diabetes showed that COX2 but not 
COX1 contributes to Up4A-increased renal contraction (20). Future studies on various 
disease models are needed to further explore our understanding of these mechanisms. As 
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reported earlier that TXA2 production is abundant in mouse aorta at basal conditions (32) 
and Up4A is capable of producing TXA2 in renal arteries of rats (20), Up4A may also 
potentially increase TXA2 in mouse aorta causing vasoconstriction. Indeed, Up4A-induced 
aortic contraction was significantly reduced by both TP antagonism and TX synthase 
inhibition, suggesting that Up4A-induced contraction in mouse aorta is not only attributed to 
TP activation but also to TXA2 production. These findings are further supported by the 
observation that Up4A-increased TXA2 level in intact isolated mouse aorta was largely 
decreased by TXA2 sysnthase inhibition. Together with the involvement of COX1, these 
findings support our hypothesis that TXA2, likely derived from COX1 activation, 
contributes to Up4A-mediated aortic contraction in mouse aorta.
As a novel extracellular dinucleotide, the vascular effects of Up4A observed in previous 
studies have been challenged to be through its degradation to ATP or adenosine (3, 5, 11). 
Although both ATP and activation of ARs have been shown to produce aortic contraction 
through generation of TXA2 (19, 31), ATP (31) and activation of ARs (19) affected vascular 
tone much less (~50% and ~30%, respectively) than Up4A (>70%), indicating that these 
degradation products can only account for a small part, if any, of the Up4A effects, as 
proposed that Up4A might also be a stimulator of endothelial ATP release (3).
Like other nucleotides, Up4A exerts its vascular influence through activation of purinergic 
receptors (3, 4). Thus, Up4A induces vasoconstriction in rat perfused kidney through P2X1R 
and P2Y1R (10), in rat aorta through P1R and P2XR (5), and in rat pulmonary arteries 
through P2YR (6), while Up4A produces vasodilation in rat perfused kidney through P2Y1R 
and P2Y2R (10), in porcine coronary arteries through A2AAR, P2X1R and P2Y1R (12) and 
in human and mouse colon through P2Y1R (30). Surprisingly, Up4A-mediated vascular 
contraction in mouse aorta in the present study was not affected by A3AR deletion, although 
one of our previous observations showed that activation of A3AR contributes to mouse 
aortic contraction (19). Moreover, Up4A-induced aortic contraction was significantly 
potentiated by either A1AR or A1/A3AR deletion, which was further supported by an 
enhancing effect with pharmacological inhibition of A1AR (DPCPX). The enhancement 
with DPCPX in Up4A-induced aortic contraction in WT was greater than that in A1AR KO 
or A1/A3AR DKO mice. This difference in enhancement between pharmacological agent in 
WT and genetically modified mice is likely due to the upregulation of other purinergic 
receptors in A1AR KO or A1/A3AR DKO that compensates for the loss of A1AR (28), as we 
previously showed that there is an upregulation of A2BAR in A1AR KO mice (28). The 
vasodilator A2BAR is likely activated by Up4A to counteract the unveiled vasoconstrictor 
effect due to the loss of A1AR, thereby leading to a less enhancement of Up4A effect in 
A1AR KO or A1/A3AR DKO as compared to that with DPCPX in WT. Taken together, 
these findings suggest that A3AR does not appear to be involved in Up4A-induced aortic 
contraction, and activation of A1AR may exert a vasodilator influence in this process. In 
contrast to the generally accepted role of A1AR exerting a vasoconstrictor influence in the 
cardiovascular system (28, 35, 36), several previous studies have shown that selective A1AR 
agonist induces vasodilation in porcine coronary arteries (37), adenosine-mediated 
activation of A1AR leads to vasodilation in rat diaphragmatic arterioles (38) and activation 
of A1AR by adenosine contributes to hypoxia-induced vasodilation in perfused rabbit hearts 
(39). Moreover, at cellular levels, activation of A1AR has been shown to mediate release of 
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NO from the endothelium of rat aorta (40). However, we could not exclude the involvement 
of vasodilator influence of A1AR in Up4A-induced aortic contraction is through other 
indirect mechanisms, as the interaction between A1AR and P2Y1R exists (41). Activation of 
P2Y1R has been shown to exert a vasodilator influence in vasculature. Thus, Up4A activates 
P2Y1R to produce vasodilation in rat perfused kidney (10), porcine coronary arteries (12), as 
well as human and mouse colons (30). Future studies addressing the role of A1AR in this 
process will bring greater insights into the purinergic receptor-regulated vascular tone.
In contrast to the observations that neither A1AR nor A3AR exerts a vasoconstrictor 
influence contributing to Up4A-induced aortic contraction, activation of P2X1R, at least in 
part, accounts for Up4A-induced vascular contraction in mouse aorta, as evidenced by a 
significant attenuation of Up4A-induced aortic contraction by both non-selective P2R 
antagonist PPADS as well as selective P2X1R antagonist MRS2159. The involvement of 
P2X1R in this process is in agreement with previous studies that activation of P2X1R 
contributes to both Up4A-mediated contraction in renal arteries (3) and NADPH-mediated 
contraction in aorta (42). Furthermore, there is some evidence linking TXA2 production or 
TP activation to activation of P2R. Thus, P2XR-agonist-induced vasoconstriction was 
attenuated by TXA2 antagonist in canine basilar arteries through endothelium-dependent 
mechanism (15), activation of both P2Y1R and P2Y2R produced vasoconstriction in human 
umbilical and chorionic vessels, which was blunted by TP antagonist (16), and ATP-induced 
contraction in rat aorta was attenuated by TP antagonist (31). Consistent with these 
observations, in the present study, Up4A increased TXA2 production in isolated aorta was 
inhibited by P2X1R antagonist MRS2159. Of note, Up4A-induced aortic contraction was 
significantly attenuated by MRS2159, which was further blunted by addition of TX synthase 
inhibitor ozagrel. Our findings suggest that Up4A-induced aortic contraction mediated by 
TXA2 is, in part, through activation of P2X1R. The reduction of Up4A-induced aortic 
contraction by P2X1R antagonist MRS2159 was similar in magnitude to that obtained by 
non-selective P2R antagonist PPADS, which could not exclude the possibility of 
involvement of additional P2R subtypes (both P2XR and P2YR) other than P2X1R in Up4A-
mediated aortic contraction. Since PPADS blocks most, but not all, of P2R subtypes, and 
PPADS does not inhibit P2X1R, as evidenced by precious studies that PPADS blocked 
P2X2R, P2X3R, P2X5R (43), P2X7R (44), P2Y1R (45), P2Y2R, P2Y4R (46) and P2Y6R 
(47). Notably, P2X1R-mediated renal vasoconstriction in response to Up4A was not blocked 
by PPADS but blocked by another non-selective P2R antagonist suramin (10). The 
limitation for the relation between TXA2 generation and activation of P2X1R is that whether 
the generation of TXA2 in response to Up4A was truly of endothelial origin or from the 
transcellular metabolism of endoperoxide is unknown, as various prostaglandins contract the 
smooth muscle cells by activating TP (31). On the other hand, methodological intricacies are 
compounded by lack of selective P2X1R agonist to explore in detail the coupling of TXA2 
production to activation of P2X1R (16). Future studies regarding this issue will confirm the 
coupling between TXA2 production and P2X1R activation.
P2R in the vasculature are present on endothelial cells as well as vascular smooth muscle 
cells (VSMC). Activation of P2R on endothelial cells is generally accepted to produce 
vasodilation, whereas activation of P2R on VSMC leads to vasoconstriction (48). Indeed, 
previous studies have shown that activation of endothelial P2X1R in response to Up4A 
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results in vasodilation in porcine coronary arteries (12), whereas activation of P2X1R by 
Up4A on VSMC produces vasoconstriction in rat perfused kidney (3, 4). In contrast to this 
concept, the observation that endothelium-denudation almost fully attenuated Up4A-induced 
aortic contraction both in the absence and presence of P2X1R or TXA2 inhibition indicates 
that Up4A-induced contraction is mainly endothelium-dependent, and Up4A generates 
TXA2 production requiring activation of P2X1R on endothelial cells. Similar phenomenon 
has been observed in rat aorta in which activation of endothelial P2XR by ATP leads to 
endothelial TXA2 production (31), and activation of P2X1R located on endothelial cells has 
been shown to contribute to NADPH-mediated vascular contraction in mouse aorta (42).
5. Conclusions
The present study demonstrates that Up4A-induced vascular contraction in mouse aorta is 
attributed to TXA2 production, which partially requires activation of P2X1R through an 
endothelium-dependent mechanism. As plasma levels of Up4A in juvenile hypertensive 
subjects are significantly elevated (13) and intra-aortic injection of Up4A increases mean 
arterial blood pressure in intact animal (3), suggesting a role for Up4A in pathogenesis of 
hypertension, further studies investigating the altered vascular responses to Up4A in 
hypertensive conditions and the contribution of TXA2 to Up4A-mediated changes in blood 
pressure will provide novel therapeutic targets in this process.
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Effects of non-selective cyclooxygenase (COX), selective COX1 and COX2 inhibition on 
Up4A-induced vasoconstriction. Shown are the concentration-responses to Up4A in mouse 
aorta from wild-type (WT) mice in the absence and presence of 10 µM of the non-selective 
COX inhibitor indomethacin (Indo) (n=13 for both Con and Indo; panel A), 10 nM of the 
selective COX1 inhibitor SC560 (n=11 for Con; n=12 for SC560; panel B), and 1 µM of the 
selective COX2 inhibitor NS398 (n=11 for Con; n=10 for NS398; panel C). The aortic rings 
in different protocols within panels are paired; the Up4A concentration responses for each 
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control are similar to those within figures or in other figures. Values are means ± SEM. * P 
< 0.05, effect of drug vs. control (Con). * represents the concentration-response relation by 
two-way ANOVA.
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Effects of thromboxane (TXA2) synthase inhibition and TXA2 receptor (TP) antagonism on 
Up4A-induced vasoconstriction. Shown are concentration-responses to Up4A in mouse aorta 
from WT in the absence and presence of 10 µM of the TX synthase inhibitor ozagrel (n=11 
for both Con and ozagrel; panel A), and 1 µM of the TP antagonist SQ29548 (n=8 for Con; 
n=6 for SQ29548; panel B). The aortic rings in different protocols within panels are paired; 
the Up4A concentration responses for each control are similar to those within figures or in 
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other figures. Values are means ± SEM. * P < 0.05, effect of drug vs. Con. * represents the 
concentration-response relation by two-way ANOVA.
Zhou et al. Page 18














Effects of A1 adenosine receptor (AR) deletion or antagonism, A3AR deletion and combined 
A1AR and A3AR deletion on Up4A-induced vasoconstriction. Shown are concentration-
responses to Up4A in mouse aorta from A3AR knockout (KO) mice (n=15 in WT; n=6 in 
A3AR KO; panel A), A1AR KO mice (n=15 in WT; n=6 in A1AR KO; panel B), and A1/
A3AR double KO (DKO) mice (n=15 in WT; n=11 in A1/A3AR DKO; panel C), as well as 
in mouse aorta from WT in the absence (n=10) and presence of 10 nM of selective A1AR 
antagonist DPCPX (n=4; panel D). The aortic rings in different protocols within panels are 
paired; the Up4A concentration responses for each control are similar to those within figures 
or in other figures. Values are means ± SEM. * P < 0.05 vs. Con or WT. * represents the 
concentration-response relation by two-way ANOVA.
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Effects of non-selective purinergic P2 receptor (P2R) antagonism and selective P2X1R 
antagonism on Up4A-induced vasoconstriction. Shown are concentration-responses to Up4A 
in mouse aorta from WT in the absence and presence of 10 µM of non-selective P2R 
antagonist PPADS (n=8 for Con; n=7 for PPADS; panel A) and 30 µM of the selective 
P2X1R antagonist MRS2159 (n=6 for Con; n=7 for MRS2159; panel B). The aortic rings in 
different protocols within panels are paired; the Up4A concentration responses for each 
control are similar to those within figures or in other figures. Values are means ± SEM. * P 
Zhou et al. Page 20













< 0.05, effect of drug vs. Con. * represents the concentration-response relation by two-way 
ANOVA.
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Effects of P2X1R antagonism, TX synthase inhibition and combined P2X1R and TXA2 
inhibition. Shown are concentration-responses to Up4A in mouse aorta from WT in the 
absence (n=6) and presence of 30 µM of the P2X1R antagonist MRS2159 (n=7), 10 µM of 
the TXA2 antagonist ozagrel (n=6) and combine MRS2159 and ozagrel (n=6). The control 
curve and MRS2159 curve are the same as those in Fig. 4B. The aortic rings in different 
protocols in the figure are paired; the Up4A concentration responses for control are similar 
to those in other figures. Values are means ± SEM. * P < 0.05 vs. Con; † P < 0.05 vs. 
MRS2159. * represents the concentration-response relation by two-way ANOVA.
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Endothelium-dependency of vasoconstriction induced by Up4A. Shown are concentration-
responses to Up4A in endothelium-non-denuded (n=7), endothelium-denuded rings and 
endothelium-denuded aortic rings from WT in the absence (n=5) and presence of 30 µM of 
the selective P2X1R antagonist MRS2159 (n=5) or 10 µM of the TX synthase inhibitor 
ozagrel (n=7). The aortic rings in different protocols in the figure are paired; the Up4A 
concentration responses for control are similar to those in other figures. Values are means ± 
SEM. * P < 0.05 vs. Con. * represents the concentration-response relation by two-way 
ANOVA.
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Effects of Up4A on TXA2 production. Shown are effects of Up4A (3 µM) on production of 
TXB2, a metabolite of TXA2, in intact isolated aortic rings from WT in the absence and 
presence of 30 µM of the selective P2X1R antagonist MRS2159 or 10 µM of the TX 
synthase inhibitor ozagrel. N=6 in each group. Values are means ± SEM. * P < 0.05 vs. 
Vehicle; † P < 0.05 vs. Up4A by one-way ANOVA.
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